European Biotech Acquisition Corp.

European Biotech Acquisition Corp. (Nasdaq: EBAC) was a blank-check company formed to pursue a business combination with targets in the European life sciences and biotechnology sector. The SPAC completed its initial public offering in 2021 and was sponsored by European Biotech Acquisition Corp. Sponsor LLC. In March 2023, the company filed a Form 15-12G with the SEC to terminate its reporting obligations under Section 12(g) of the Securities Exchange Act, indicating it wound down without completing a merger or acquisition. EBAC joins a cohort of life-sciences-focused SPACs that did not consummate a deal amid a broadly challenging deal environment in 2022 and 2023. Sign up at SpacDesk for the full filing history, timeline, and sponsor profile on EBAC and hundreds of other SPACs.